- Home
- EYEN vs AWH Comparison
EYEN vs AWH Comparison
Compare EYEN & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- AWH
- Stock Information
- Founded
- EYEN 2014
- AWH 1993
- Country
- EYEN United States
- AWH United States
- Employees
- EYEN N/A
- AWH N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- AWH Medical/Dental Instruments
- Sector
- EYEN Health Care
- AWH Health Care
- Exchange
- EYEN Nasdaq
- AWH Nasdaq
- Market Cap
- EYEN 9.2M
- AWH 10.5M
- IPO Year
- EYEN 2018
- AWH N/A
- Fundamental
- Price
- EYEN $0.06
- AWH $0.50
- Analyst Decision
- EYEN Hold
- AWH Buy
- Analyst Count
- EYEN 4
- AWH 2
- Target Price
- EYEN $2.00
- AWH $4.40
- AVG Volume (30 Days)
- EYEN 49.5M
- AWH 100.3K
- Earning Date
- EYEN 11-12-2024
- AWH 11-14-2024
- Dividend Yield
- EYEN N/A
- AWH N/A
- EPS Growth
- EYEN N/A
- AWH N/A
- EPS
- EYEN N/A
- AWH N/A
- Revenue
- EYEN $31,832.00
- AWH $8,963,000.00
- Revenue This Year
- EYEN $23,413.60
- AWH $11.87
- Revenue Next Year
- EYEN $400.98
- AWH $79.10
- P/E Ratio
- EYEN N/A
- AWH N/A
- Revenue Growth
- EYEN 2557.10
- AWH N/A
- 52 Week Low
- EYEN $0.06
- AWH $0.38
- 52 Week High
- EYEN $2.57
- AWH $5.65
- Technical
- Relative Strength Index (RSI)
- EYEN 35.58
- AWH 27.14
- Support Level
- EYEN $0.06
- AWH $0.38
- Resistance Level
- EYEN $0.09
- AWH $0.79
- Average True Range (ATR)
- EYEN 0.03
- AWH 0.07
- MACD
- EYEN 0.00
- AWH -0.02
- Stochastic Oscillator
- EYEN 1.58
- AWH 27.91
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.